^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
The NCCN Panel has included bevacizumab as a therapeutic option for patients with non-clear RCC (2A).
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
…the NCCN Panel recommends bevacizumab plus everolimus (category 2A) for select patients with advanced RCC with non- clear cell histology.
Secondary therapy:
everolimus